About Convelo:

Convelo:
Who We Are

ABOUT US

A Name Rooted in a Powerful Vision

Convelo, derived from the Latin words for ‘enveloping’ and ‘encircling’, symbolizes our mission more than just a name. At Convelo Therapeutics, we’re pioneering a groundbreaking class of medicines aimed at harnessing the central nervous system’s latent regenerative power.

Embark on this journey with us and be part of shaping the future of neuro-regeneration. Our founders, Paul Tesar and Drew Adams, bring:

10+

Patents related to
treatment of MS

100+

Authorship of research publications

Guiding our mission is a top-tier biotech leadership team, led by Derrick Rossi. Together, they bring:

Average of 10+ years of experience in drug discovery

Multiple drugs in clinical stages

A track record of academic and industry accolades

OUR ETHOS

Excellence, Innovation, Community

Our ethos mirrors our name – encompassing and impactful. We embody these principles in each project, medicine, and partnership, driven by a relentless pursuit of scientific distinction. Our journey in developing innovative medicines, particularly for Multiple Sclerosis, is a testament to this dedication.

But our vision transcends medicine. We’re deeply invested in Cleveland’s future, cultivating talent from its academic and healthcare landscapes. For us, excellence is not a goal but a tradition, shaping a healthier future for all.

OUR JOURNEY

From Lab Neighbors to Biotech Success

In the corridors of Case Western Reserve University, Paul Tesar, PhD, and Drew Adams, PhD, bonded over a shared, insatiable curiosity. This curiosity-driven partnership led to a significant discovery in oligodendrocyte differentiation, which eventually laid the groundwork for the formation of Convelo Therapeutics in 2016.

Our story took a dynamic turn in 2016 when Derrick Rossi, PhD, recognized the potential of this collaboration and Convelo Therapeutics was formally founded. It was a natural progression of this partnership, with an aim to turn innovative research into real-world solutions for neurodegenerative diseases.

Quickly, Convelo garnered a significant $7.8M Series A funding in 2018. The momentum continued with a strategic alliance with Genentech in 2019 and a $12.2M Series B funding in 2022, further cementing our standing in the field.

Today, from our Cleveland-based R&D lab, we continue to innovate and collaborate, driven by a serendipitous partnership and a relentless commitment to health.